Charles Schwab
CAPR icon

Charles Schwab’s Capricor Therapeutics CAPR Stock Holding History

Charles Schwab’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.88M Buy
160,938
+34,915
+28% +$1.06M ﹤0.01% 2575
2026
Q1 		$3.83M Buy
126,023
+6,671
+6% +$178K ﹤0.01% 2506
2025
Q4 		$3.44M Sell
119,352
-933
-0.8% -$12.2K ﹤0.01% 2591
2025
Q3 		$867K Hold
120,285
– – ﹤0.01% 3003
2025
Q2 		$1.19M Buy
120,285
+6,635
+6% +$70.1K ﹤0.01% 2841
2025
Q1 		$1.08M Buy
113,650
+2,314
+2% +$32.1K ﹤0.01% 2810
2024
Q4 		$1.54M Buy
111,336
+37,868
+52% +$664K ﹤0.01% 2755
2024
Q3 		$1.12M Hold
73,468
– – ﹤0.01% 2885
2024
Q2 		$350K Buy
73,468
+59,989
+445% +$334K ﹤0.01% 3326
2024
Q1 		$91.5K Hold
13,479
– – ﹤0.01% 3313
2023
Q4 		$65.9K Hold
13,479
– – ﹤0.01% 3380
2023
Q3 		$46.1K Hold
13,479
– – ﹤0.01% 3413
2023
Q2 		$64.4K Hold
13,479
– – ﹤0.01% 3385
2023
Q1 		$56.9K Buy
+13,479
New +$58K ﹤0.01% 3329
2022
Q3 		– Sell
-14,832
Closed -$52K – 3514
2022
Q2 		$52K Hold
14,832
– – ﹤0.01% 3386
2022
Q1 		$51K Buy
+14,832
New +$58.5K ﹤0.01% 3526
2021
Q1 		– Sell
-14,545
Closed -$50K – 3493
2020
Q4 		$50K Hold
14,545
– – ﹤0.01% 3351
2020
Q3 		$77K Buy
+14,545
New +$84.8K ﹤0.01% 3257

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Charles Schwab's CAPR Position: Q2 2026 in Review

Charles Schwab increased its Capricor Therapeutics (CAPR) stake by 28% in Q2 2026, buying an estimated $1.06M and bringing the position to 160,938 shares worth $3.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2575.

Charles Schwab first reported a position in CAPR in Q3 2020 and has held it in 18 quarters since. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Charles Schwab held 160,938 shares of Capricor Therapeutics worth $3.88M as of Q2 2026.
  • Charles Schwab bought 34,915 Capricor Therapeutics shares in Q2 2026, an estimated $1.06M.
  • Capricor Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2575 holding.
  • Charles Schwab first reported a position in Capricor Therapeutics in Q3 2020 and has held it in 18 quarters since.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.